107 results about "Drug reaction" patented technology

The invention provides means to determine the predisposition of individuals to adverse drug reactions (ADRs). The methods are based on genotyping or parallelized enzyme and protein profiling or both. Parallelized enzyme activity profiling can be used for drug screening and development. As examples of the invention we show the prediction of adverse drug reactions of pulmonary hypertension patients by identifying genes and alleles linked to known ADRs and liver enzyme reaction profiling with ADR correlation.

The invention relates to a gene chip used for detecting gene mutation relating to a high blood pressure personalized medicine. The gene chip for detecting the gene mutation relating to high blood pressure personalized medicine comprises a solid phase support, a gene probe (an oligonueleotide probe) fixed in the solid phase support sequentially and a PCR primer used for amplifying the mutated gene fragment in the sample; the gene probe (the oligonueleotide probe) and the PCR primer are designed aiming at one or two points of the gene mutation in ACE (I/D) and CYP3A5*3 and / or two or more points as follows: CYP2C9*3, CYP2C9*13, AGTR1(A1166C), CYP2D6*10, ADRB1(C1165G), TSC(C1784T), ADRB3(T727C), SCNN1G_rs5729, SCNN1G_rs5723, ENOSA_rs1799983 and GNB3(C825T). The invention provides the gene chip and applications thereof for conveniently, quickly and systematically detecting the gene mutation relating to high blood pressure personalized medicine so as to determine drug reactions.

The present invention provides a drug for the treatment of thrombocytopenia caused by hepatic failure, preferably a drug with few adverse drug reactions. A substance that inhibits binding between glycoprotein Ib (GPIb) and von Willebrand factor (vWF), for example, anti-GPIb antibody or anti-vWF antibody that inhibits binding between GPIb and vWF is an active ingredient of the drug for the treatment of thrombocytopenia.

The invention relates to an anticancer slow-release gel injection which contains slow-release microspheres containing an angiogenesis inhibitor, an amphiphilic block polymer, a solvent and a slow-release agent, wherein the composition of the amphiphilic block polymer and the non-organic solvent exhibit the property of temperature-sensitive gelation. After the in vivo injection, the injection turns into a stagnant and biodegradable water-insoluble gel and the gel slowly releases the drug contained therein for a plurality of weeks to a plurality of months. After the intratumoral or peritumoral injection, the anticancer slow-release gel injection can significantly reduce the general drug reactions and is used for treating tumors of different stages. The angiogenesis inhibitor is selected from SU5416, SU6668, bosutinib, sprycel, erlotinib, vandetanib, gefitnib, canertinib, lapatinib, lestaurtinib, masitinib, vatalanib, mubritinib, tandutinib, nilotinib, marimastat, nilotinib, pelitinib, telatinib, sunitinib, sorafenib, zarnestra, sirolimus, imatinfb, lenalidomide and thalidomide.

A process for restoring responsiveness to medication in eye tissue, namely retinal tissue, that is unresponsive to medication. The process utilizes a laser source for generating a confluent, contiguous laser light beam. The laser light beam is preferably a subthreshold diode micropulse laser beam which is optically shaped through an optical lens or mask. The tissue is then exposed to the confluent, contiguous laser light beam and allowed to recover for thirty days before administering medication to which the tissue was unresponsive.

The present invention is a system and method for utilizing human genetic and genomic information to guide prescription dispensing and improved drug safety in a pharmacy setting. The system and method of the present invention utilizes a dedicated information management system and software to utilize patient-specific genetic information to screen for increased risk of adverse drug reactions and therapeutic responses at the time of drug dispensing.

The invention belongs to the technical field of medicinal preparations and nano medicine preparation and relates to the micelles and freeze-dried preparations of diblock polymer-supported taxane medicines and preparation and use thereof. For using the micelles in clinic, the medicine load capacity, encapsulation rate and stability of the preparation are required to be ensured. The micelles are prepared from 1.5 to 99 parts of methoxypolyethylene glycol (MPEG)-polycaprolactone (PCL) diblock polymer and 1 part of taxane medicines; and in the diblock polymer, the molecular weight ratio of the MPEG to the PCL is 0.5 to 2. The micelles and freeze-dried preparations of taxane medicines can be used for treating patients with cancers, tumors, Kaposi sarcoma, malignant tumors, tissue and cell hyperplasia due to tissue injuring disorder, and any of other diseases that can react with taxane medicines, and the treatment effects of the micelles and freeze-dried preparations are obvious particularly on hepatocellular carcinoma, ovarian cancer and breast cancer.

The invention provides an application of a carbon dot as an anti-tumor medicine carrier. The application comprises the following steps: preparing an aminated carbon dot: by taking a silane reagent containing amino groups and glycerin as raw materials, preparing the aminated carbon dot by adopting a microwave synthesis process; performing maleimide treatment on the surface of the carbon dot: reacting the aminated carbon dot with a short-chain polyethylene glycol molecule NHS-EGn-MAL of which one end has N-hydroxysuccinimide ester and the other end has maleimide to obtain the carbon dot subjected to maleimide treatment; and preparing a carbon dot-medicine molecule complex: reacting the carbon dot subjected to maleimide treatment with a medicine with sulfhydryl groups to obtain the carbon dot-medicine molecule complex. The aminated carbon dot prepared by using a method provided by the invention is high in fluorescence quantum yield, good in water solubility and low in cytotoxicity, has a great number of modifiable genes on the surface, cannot cause coagulation after modifying a short-chain polyethylene glycol chain segment, and is a very ideal medicine carrier.

The present invention relates to a web-based computer-aided method and a system for providing personalized recommendations about drug use, based on pharmacogenetic information regarding genes and genetic variants associated to metabolism and genes and genetic variants which are not associated to metabolism, and which comprises automatically generating and displaying, by means of a graphical user interface (GUI) of a dynamic webpage, the personalized recommendations highlighting the ones associated to the highest adverse drug reactions.

The present invention also relates to a computer-readable medium which contains program instructions for a computer to perform the method for providing personalized recommendations about drug use of the invention.

The present invention also relates to a web-based computer-aided method and a system for generating a dynamic webpage, and a further computer-readable medium which contains program instructions for a computer to perform the method for generating a dynamic webpage.

The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly Drug-Induced Liver Injury (DILI) or hepatotoxicity. The invention also provides a method of identifying a subject afflicted with, or at risk of, developing DILI. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing DILI.

The present invention provides systems and methods for determining enzymatic competency, which is important in determining whether a patient may suffer an adverse drug reaction, has a disease associated with defects in specific enzymatic function, and/or has an enzyme defect that is likely to cause pathophysiology. As contemplated herein, a parent molecular entity is administered to a patient in whom enzymatic competency is to be determined. A sample of the patient's bodily fluid is exposed to a sensor of the invention to distinguish, detect, and quantify a detectable entity in the bodily fluid. Sensor-acquired data regarding the detectable entity is used to determine enzymatic competency. Preferably, a sample of a patient's exhaled breath is collected and exposed to the sensor of the invention. Types of sensor systems of the invention include, but are not limited to, surface resonance arrays; microelectromechanical sensors (such as microcantilever-based technology); molecularly imprinted polymer sensors; amplifying fluorescent sensor technology; aptamer-based sensor technology; SAW sensors; infrared sensors; fuel cells; chemical reactors; and pH sensitive sensors.

Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A₂ (sPLA₂) hydrolysable, cisplatin-containing liposome composition (e.g., LiPlaCis). The patient may be assessed for their responsiveness to the liposomal therapy prior to treatment using the methods, devices, and kits also described herein for detecting a level of one or more biomarkers in a sample from the patient with cancer.

A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including CYP2C9, CYP2C19, CYP2C8 and CYP2C18), HLA alleles (including HLA-A*0207, HLA-A*2402, HLA-B*1301, HLA-B*1502, HLA-B*4001, HLA-B*4609, HLA-B*5101, HLA-DRB1*1001 or HLA-DRB1*1502) and phenytoin concentration in the patient's plasma can all contribute to phenytoin-induced ADRs.

The invention discloses a method for establishing an experimental model of a diabetic foot ulcer big mouse infected by staphylococcus aureus. The method includes the following steps that after the big mouse is fed on high-fat diet for eight weeks, streptozotocin is injected, and a diabetic model is manufactured. After the diabetic model is stabilized, II-degree scalding is performed on the skin of the big mouse, and after three days, subcutaneous injection of suspension liquid with staphylococcus aureus as the bacterial strain is performed in each ulcer position. In addition, the invention further discloses a kit for establishing the experimental model of the diabetic foot ulcer big mouse infected by the staphylococcus aureus, wherein the kit comprises the staphylococcus aureus suspension liquid. The diabetic foot ulcer experimental animal model detects variation of biochemical indexes after pharmacological intervention, and a result shows that the model has the infection features of diabetic foot ulcer and concurrent gram-positive bacteria. The model has the advantages of being short in ulcer wound surface healing time, sensitive to drug reaction and the like.

The invention relates to a slow-release injection containing bortezomib and topoismerase inhibitors. The slow-release injection is composed of slow-release microspheres and a solvent, wherein the slow-release microsphere contains an anticancer effective component selected from bortezomib and topoismerase inhibitor and a slow-release adjuvant, and the solvent is a common solvent or a special solvent containing suspending agent. The viscosity of the suspending agent is in the range from 100cp to 3000cp at a temperature ranging from 20 DEG C to 30 DEG C. The suspending agent is preferably sodium carboxymethylcellulose. The slow-release adjuvant is selected from a copolymer of poly(phosphate ester) (such as p(LAEG-EOP) and p(DAPG-EOP)) or a copolymer or a blend of poly(phosphate ester) and PLA or polifeprosan or PLGA or poly(erucic acid dipolymer-sebacic acid). The topoismerase inhibitor is selected from camptothecin, hydroxycamptothecine, topoteean, lurtotecan, irinotecan, etoposide and teniposide. The anticancer composition is also formulated as slow-release implant. After the intratumoral or peritumoral injection or implantation, the effective blood concentration lasts more than 60 days. Additionally, the slow-release injection can significantly reduce the general drug reaction and selectively enhance the chemotherapeutic effect, particularly the effect of non-operative treatment such as local radiotherapy. The slow-release injection is used for the treatment of various solid tumors.

The invention relates to the field of biological detection and discloses a detection device and a detection method of a large class of beta-agonists drugs by applying an immune chromatography technology. According to the invention, an antibody/receptor which is reacted with a large class of the beta-agonists drugs is used for preparing an immune chromatography test strip to realize the simultaneous detection of a large class of the beta-agonists drugs. Compared with the prior art, the detection on a large class of the beta-agonists drugs for one time can be realized, the detection cost is low and the method is convenient and fast.

The invention discloses a novel nano-drug with a tumor treatment action and a preparation method. The preparation method comprises the steps of carrying adriacin doxorubicin with hollow mesoporous SiO2 nanoparticles (HMSNs), and then treating with bicarbonate to obtain nano-bomb. When drug enters cell lysosome by endocytosis, H<+> in the lysosome reacts with the drug and fast generates CO2 gas; the generated gas damages completeness of the lysosome or improves the permeability of a lysosome membrane, induces the death of cells related to the lysosome, therefore, cancer cells are killed. The nano-bomb also has well treatment effect for drug-resistant strains, and can effectively overcome tolerance of the cancer cells.

The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism. The method is useful for predicting susceptibility of an AD patient to chemicals based on genes and for selecting the diagnostic and/or therapeutic agent by eliminating harmful drug reactions from the analysis of principal factors related to onset and development of AD and interaction among these genes, and for determining a diagnostic method and therapeutic method using the detection method of morbidity risk.

The invention discloses a biological photosensitizer, and a preparation method and application thereof. The photosensitizer has the targeting ability of the photosensitizer and the characteristic of killing tumour cells, can also activate an epidermal growth factor receptor in a tissue of a living body, can kill tumour tissues, and meanwhile, can promote tissue healing; the biological photosensitizer can kill squamous-cell carcinoma efficiently and quickly, and can promote skin repairing; side effects of drug reaction are extremely low.

The invention discloses a bone targeting medicinal vector and medicament. The bone targeting medicament vector is prepared by the following steps of: oxidizing glucan into glucan oxide containing a poly-aldehyde group with sodium periodate; and making diphosphonic acid containing an amino group react with the glucan oxide containing the poly-aldehyde group. The medicament with a bone targeting property is obtained by the following steps of: making the bone targeting medicament vector react with a medicament containing an amino group; and connecting the glucan oxide containing the poly-aldehyde group serving as an intermediate with diphosphonic acid with a bone guiding function and other medicaments (except diphosphonic acid) containing amino groups, wherein the prepared bone targeting medicament has high bone affinity and large medicament loading capacity when the reaction mass ratio of the diphosphonic acid to the glucan oxide aldehyde group is (0.4-0.6):1. The bone targeting medicament acts on bone tissues in an oriented way under the guiding action of the diphosphonic acid, and has different treating effects by loading different medicaments. The bone targeting medicament has the advantages of large medicament loading capacity, high bone affinity, simple synthesizing steps and easiness for controlling conditions.

The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.